BKCYF yields 7.19% · JNJ yields 2.13%● Live data
📍 BKCYF pulled ahead of the other in Year 1
Combined, BKCYF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BKCYF + JNJ for your $10,000?
Bank of Cyprus Holdings Public Limited Company, through its subsidiaries, provides banking, financial, and insurance services. It offers current, savings, notice, instant access, and fixed deposits; housing, student, consumer, business and business premises, term, and home or investment loans; and asset finance, factoring, trade facilities, European financial, project finance, shipping finance, and syndicated and corporate lending services, as well as hire purchase services for car and equipment. The company also provides debit, credit, prepaid, and special cards; reward programs; digital products; digital banking, and payments and services; motor, home, business, life, create capital, and health insurance products; SME guarantee facility services; day to day banking services; investment banking and brokerage, asset and wealth management, market execution and hedging, and structured and funding solutions; investment products and services; and custody and depositary services. In addition, it is involved in the property trading and development activities; land development and operation of a golf resort; management administration and safekeeping of UCITS units; administration of guarantees and holding of real estate properties; collection of the existing portfolio of receivables, including third party collections; and provision of card processing transaction, auction, and secretarial services. As of June 30, 2022, the company operated 86 branches in Cyprus. Bank of Cyprus Holdings Public Limited Company was founded in 1899 and is headquartered in Nicosia, Cyprus.
Full BKCYF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.